Ophthalmology Doctors in Vista, CA Accepting Medicare

7 Ophthalmology doctors found. Showing 1 - 7

Benjamin Hutton Stephens, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2067 W Vista Way Ste 120, Vista, CA 92083 Phone: 760-758-2020    Fax: 760-758-1410

Heather Chen, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2067 W Vista Way Ste 120, Vista, CA 92083 Phone: 760-758-2020

Dr. Bradley William Greider, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2067 West Vista Way, Ste 120, Vista, CA 92083 Phone: 760-758-2020    Fax: 760-758-1410

Mark Soontornvachrin, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 780 Shadowridge Dr, Vista, CA 92083 Phone: 844-424-1867

William Jerrard Dunnigan, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2482 Vista Valley Lane, Vista, CA 92084 Phone: 760-945-5473

Maulik Subhash Zaveri, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2067 W Vista Way Ste 120, Vista, CA 92083 Phone: 760-758-2020    Fax: 760-758-1410

Kelsi Leigh Greider-sideris, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2067 W Vista Way Ste 120, Vista, CA 92083 Phone: 760-758-2020    Fax: 760-758-1410

News Archive

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.

Biocompatibility of interactions that occur between implanted biomaterials and the host living tissue

Researchers across the world are working toward biocompatibility by optimizing interactions that occur between implanted biomaterials and the host living tissue.

The OpenHIE community to hold second annual community meeting in Ethiopia

The OpenHIE community will hold its second annual community meeting November 4-8, 2019 in Addis Ababa, Ethiopia. Between 200 and 300 individuals are expected to attend with the ultimate goal of development and efficient and effective operation of national and regional health information exchanges.

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015.

Read more Medical News

› Verified 8 days ago